about
Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic ImplicationsMultiple roles for nicotine in Parkinson's diseaseThe sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanismTrace Amines and the Trace Amine-Associated Receptor 1: Pharmacology, Neurochemistry, and Clinical ImplicationsNeuropharmacological Potential of Gastrodia elata Blume and Its ComponentsPharmacological Treatments Inhibiting Levodopa-Induced Dyskinesias in MPTP-Lesioned Monkeys: Brain Glutamate Biochemical CorrelatesStriatal cholinergic interneuron regulation and circuit effectsFunctional neuroimaging in Parkinson's diseaseIntrastriatal transplantation of adult human neural crest-derived stem cells improves functional outcome in parkinsonian ratsLevodopa-induced dyskinesia is associated with increased thyrotropin releasing hormone in the dorsal striatum of hemi-parkinsonian ratsPharmacogenetics of antipsychotic-induced movement disorders as a resource for better understanding Parkinson's disease modifier genesOn the Complexity of Brain Disorders: A Symptom-Based Approach.Parallel dopamine D1 receptor activity dependence of l-Dopa-induced normal movement and dyskinesia in mice.L-DOPA neurotoxicity is mediated by up-regulation of DMT1-IRE expression.Assessment of Treatment Patterns and Patient Outcomes in Levodopa-Induced Dyskinesias (ASTROID): A US Chart Review Study.Deficits in cholinergic neurotransmission and their clinical correlates in Parkinson's disease.Evaluation of D2 and D3 dopamine receptor selective compounds on L-dopa-dependent abnormal involuntary movements in rats.Maladaptive striatal plasticity in L-DOPA-induced dyskinesia.Compound Formula Rehmannia alleviates levodopa-induced dyskinesia in Parkinson's disease.Dysregulation of striatal dopamine release in a mouse model of dystonia.Spontaneous locomotor activity and L-DOPA-induced dyskinesia are not linked in 6-OHDA parkinsonian rats.Influence of single nucleotide polymorphisms in COMT, MAO-A and BDNF genes on dyskinesias and levodopa use in Parkinson's disease.Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients.Development of allosteric modulators of GPCRs for treatment of CNS disordersThe safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease.Effect of zishenpingchan granule on neurobehavioral manifestations and the activity and gene expression of striatal dopamine d1 and d2 receptors of rats with levodopa-induced dyskinesias.Striatal molecular signature of subchronic subthalamic nucleus high frequency stimulation in parkinsonian rat.Commentary: Dopaminergic dysfunction in DYT1 dystonia.Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian rats.A conditioned response as a measure of impulsive-compulsive behaviours in Parkinson's disease.Objective measurement of dyskinesia in Parkinson's disease using a force plateL-DOPA-Induced Dyskinesia and Abnormal Signaling in Striatal Medium Spiny Neurons: Focus on Dopamine D1 Receptor-Mediated Transmission.Nicotine and Parkinson's disease: implications for therapy.Impact of L-DOPA treatment on regional cerebral blood flow and metabolism in the basal ganglia in a rat model of Parkinson's disease.Clinical aspects and management of levodopa-induced dyskinesia.Assessing Motor Fluctuations in Parkinson's Disease Patients Based on a Single Inertial SensorAltered Neuronal Firing Pattern of the Basal Ganglia Nucleus Plays a Role in Levodopa-Induced Dyskinesia in Patients with Parkinson's Disease.An updated meta-analysis of amantadine for treating dyskinesia in Parkinson's disease.Levodopa is not a useful treatment for Lesch-Nyhan disease.Improving the Treatment of Parkinson's Disease: A Novel Approach by Modulating 5-HT(1A) Receptors.
P2860
Q21129423-31FD44C5-41A7-4120-AB85-D719572455BBQ22252514-8097B42E-39EF-41DD-95F6-A6B21C725AB5Q24614102-BDF41423-3DE7-4B81-B57C-AD3F81FE46A7Q26752602-12E0AF74-D8C6-4840-972E-30B298735421Q26778823-8B488007-3278-4DBE-A3B9-D1767AC53DC6Q26852311-25938AFC-C4DB-4112-9BC0-0C3157E0FC73Q26863113-F1F986DA-457D-4472-BD3D-44B766BE577CQ27013767-29796829-EE0F-447F-84A7-57AF03DA2EECQ27301260-75B53C0E-5A2D-47F2-924B-1778262B4141Q27316872-5030A3B4-A154-45D8-8024-E6C820BFEE43Q28088705-92E7A24E-BF67-465A-9882-1A42CE13537BQ30389213-83AC31E0-480B-4AEA-84DD-2C594394719FQ30538394-BC59E8B9-C061-4E39-B21B-B85B75C19649Q33412141-69A4EF9D-16B3-4267-AA9B-ADC6DB6AD305Q33652773-6932C58A-AB20-4433-B2A6-726C1611E261Q33917311-08AD23F2-745E-4406-84D2-E0A6BF765FFFQ33931801-42888976-C5FE-495E-9D14-64CCCA4AB20FQ34094008-EED023CD-25BE-4BF8-A9BE-29C59813C5A4Q34095853-4455FCEB-10B4-4CAB-94DF-D96AB6E62B96Q34182068-716365FD-488C-4C56-8446-AFCE653DAA52Q34279877-29A02077-ED64-4083-B69B-A4E5655789ECQ34326909-069A7A2E-7F33-4C25-BA35-9CAB5A57EEF1Q34368806-717291A1-6C15-403E-AE00-FC9AB2F4ABDAQ34373958-47E88831-0EB7-482C-A2A2-E203BA90122FQ34512544-BF7765F6-87DC-43DE-A5C5-988287C94480Q34588665-7FE0427F-61ED-4243-BBAE-ECDDCC1374F7Q34673205-4B58AB87-9418-424F-B8E0-03855CF30245Q35009095-59B87AD8-F6E7-4D74-A9C5-2B831AFCA4ACQ35097046-82B1B0F1-8E7F-488F-BB01-66A17D4E2F51Q35107051-3D4EE763-AB60-488B-81E2-EA7C74686E44Q35140804-7199C7EE-A4C9-467C-A9A3-B78B2A7ECD90Q35424424-34EEBD68-E744-4966-840E-6AEABC6400EFQ35601652-26D5F679-006E-449D-B255-5DC3ABF0202FQ35683102-D2734E16-A765-47B9-860B-A43337F87F1BQ36022700-4E7C8538-C327-478F-8774-9442492E5BFFQ36226593-30FAA307-FD50-4754-AB45-D1E6B187E566Q36316264-818620F0-3C91-47F8-8242-459C5B2C7536Q36376607-F4303FDD-14E3-4DE1-8791-0FC3049104C9Q36471109-6DB70F91-0426-4B70-87F3-1C749CB8951AQ36603634-3ECA6657-6C40-4680-A8A4-6512050A5886
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Levodopa-induced dyskinesias.
@ast
Levodopa-induced dyskinesias.
@en
Levodopa-induced dyskinesias.
@nl
type
label
Levodopa-induced dyskinesias.
@ast
Levodopa-induced dyskinesias.
@en
Levodopa-induced dyskinesias.
@nl
prefLabel
Levodopa-induced dyskinesias.
@ast
Levodopa-induced dyskinesias.
@en
Levodopa-induced dyskinesias.
@nl
P50
P356
P1433
P1476
Levodopa-induced dyskinesias.
@en
P2093
Francisco Grandas
Masahiro Nomoto
P304
1379-89; quiz 1523
P356
10.1002/MDS.21475
P407
P577
2007-07-01T00:00:00Z